24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This 8-week, crossover study will compare the quality of 24-hour IOP control with TTFC versus
travoprost when both medications are dosed in the evening. Such a crossover comparison may
determine the real efficacy of the new fixed combination versus travoprost monotherapy. The
results should enhance the investigators understanding on the best dosing of TTFC and may
influence its clinical use in Europe. Finally, the results would better delineate the future
role of TTFC in glaucoma management after PG monotherapy, or instead of unfixed therapy with
PG analogs and timolol. This study should assist the general ophthalmologist worldwide to
plan optimal stepwise medical therapy.